| Literature DB >> 35051051 |
Claudia Landi1, Giulia Liberatori2, Pietro Cotugno3, Lucrezia Sturba2, Maria Luisa Vannuccini2, Federica Massari3, Daniela Valeria Miniero3, Angelo Tursi3, Enxhi Shaba1, Peter A Behnisch4, Alfonso Carleo5, Fabrizio Di Giuseppe6, Stefania Angelucci6, Luca Bini1, Ilaria Corsi2.
Abstract
A topsoil sample obtained from a highly industrialized area (Taranto, Italy) was tested on the DR-CALUX® cell line and the exposed cells processed with proteomic and bioinformatics analyses. The presence of polyhalogenated compounds in the topsoil extracts was confirmed by GC-MS/MS analysis. Proteomic analysis of the cells exposed to the topsoil extracts identified 43 differential proteins. Enrichment analysis highlighted biological processes, such as the cellular response to a chemical stimulus, stress, and inorganic substances; regulation of translation; regulation of apoptotic process; and the response to organonitrogen compounds in light of particular drugs and compounds, extrapolated by bioinformatics all linked to the identified protein modifications. Our results confirm and reflect the complex epidemiological situation occurring among Taranto inhabitants and underline the need to further investigate the presence and sources of inferred chemicals in soils. The combination of bioassays and proteomics reveals a more complex scenario of chemicals able to affect cellular pathways and leading to toxicities rather than those identified by only bioassays and related chemical analysis. This combined approach turns out to be a promising tool for soil risk assessment and deserves further investigation and developments for soil monitoring and risk assessment.Entities:
Keywords: bioassay; contaminants of emerging concern; polyhalogenated compounds; proteomics; risk assessment; soil pollution
Year: 2021 PMID: 35051051 PMCID: PMC8779689 DOI: 10.3390/toxics10010009
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Total concentrations of PCDDs, PCDFs, and mono-ortho and non-ortho dl-PCBs expressed as ng/kg d.w., toxic equivalents expressed as TEQWHO of 2,3,7,8-TCDD as reported in [34], and pattern profile expressed as percentage (%), calculated from GC-MS/MS analysis.
| Compound | Concentrations (ng/kg d.w.) | TEQWHO | Percentage (%) |
|---|---|---|---|
| Chlorinated dibenzo-p-dioxins | |||
| 2,3,7,8-TCDD | 3.5 | 3.5 | 5.9% |
| 1,2,3,7,8-PeCDD | 9.2 | 9.2 | 15.5% |
| 1,2,3,4,7,8-HxCDD | 4.4 | 0.44 | 0.7% |
| 1,2,3,7,8,9-HxCDD | 4.8 | 0.48 | 0.8% |
| 1,2,3,4,6,7,8-HpCDD | 25.7 | 0.257 | 0.4% |
| 1,2,3,4,6,7,8,9-OCDD | 40.2 | 0.01206 | 0% |
| Chlorinated dibenzofurans | |||
| 2,3,7,8-TCDF | 13.9 | 1.39 | 2.3% |
| 1,2,3,7,8-PeCDF | 18.9 | 0.567 | 1% |
| 2,3,4,7,8-PeCDF | 83.4 | 25.02 | 42.2% |
| 1,2,3,4,7,8-HxCDF | 50.4 | 5.04 | 8.5% |
| 1,2,3,6,7,8-HxCDF | 31.6 | 3.16 | 5.3% |
| 1,2,3,7,8,9-HxCDF | 44 | 4.4 | 7.4% |
| 2,3,4,6,7,8-HxDF | 4.6 | 0.46 | 0.8% |
| 1,2,3,4,6,7,8-HpCDF | 138.1 | 1.381 | 2.3% |
| 1,2,3,4,7,8,9-HpCDF | 5.5 | 0.055 | 0.1% |
| 1,2,3,4,6,7,8,9-OCDF | 219 | 0.0657 | 0.1% |
| Non-ortho–substituted PCBs | |||
| 3,3’,4,4’-tetraCB (PCB-77) | 16 | 0 | 0% |
| 3,4,4’,5-tetraCB (PCB-81) | 7 | 0 | 0% |
| 3,3’,4,4’,5-pentaCB (PCB-126) | 37 | 3.7 | 6.2% |
| 3,3’,4,4’,5,5’-hexaCB (PCB-169) | 5 | 0.15 | 0.3% |
| Mono-ortho–substituted PCBs | |||
| 2,3,3’,4,4’-pentaCB (PCB 105) | 47 | 0 | 0% |
| 2,3,4,4’,5-pentaCB (PCB 114) | 7 | 0 | 0% |
| 2,3’,4,4’,5-pentaCB (PCB 118) | 67 | 0 | 0% |
| 2’,3,4,4’,5-pentaCB (PCB 123) | 18 | 0 | 0% |
| 2,3,3’,4,4’,5-hexaCB (PCB 156) | 45 | 0 | 0% |
| 2,3,3’,4,4’,5’-hexaCB (PCB 157) | 10 | 0 | 0% |
| 2,3’,4,4’,5,5’-hexaCB (PCB 167) | 44 | 0 | 0% |
| 2,3,3’,4,4’,5,5’-heptaCB (PCB 189) | 11 | 0 | 0% |
|
| |||
|
| |||
Concentrations of single PAHs and their sum expressed as mg/Kg d.w. in topsoil samples, EC50 values based on DR-CALUX®, toxic equivalents expressed as reported in [35] as TEQ and percentage.
| Compound | Concentrations (mg/kg d.w.) | EC50 DR CALUX® | TEQ | Percentage (%) |
|---|---|---|---|---|
| Polycyclic Aromatic Hydrocarbons | ||||
| Pirene | 0.003 | 0% | ||
| Benzo[a]antracene | 0.00011 | 0% | ||
| Crisene | 0.004 | 0% | ||
| Benzo[b]fluorantene | 0.004 | 0.00092 | 0.00000368 | 69.4% |
| Benzo[k]fluorantene | 0.003 | 0.00054 | 0.00000162 | 30.6% |
| Benzo[a]pirene | 0.00025 | - | 0% | |
| Benzo[g,h,i]perilene | 0.003 | 0% | ||
| Dibenzo[a,h]antracene | 0.0011 | 0% | ||
| Indeno[123-c,d]antracene | - | 0.00076 | 0% | |
| Dibenzo[a,e]perilene | - | 0% | ||
| Dibenzo[a,i]perilene | - | 0% | ||
| Dibenzo[a,l]perilene | - | 0% | ||
| Dibenzo[a,h]perilene | - | 0% | ||
| ∑PAHs | 0.017 | 0.0000053 | ||
Figure 1PCA performed with the %V of the differentially abundant spots. (A) PCA considering the analyzed 3 conditions. (B) PCA considering CTRL vs. DxCS. Both analyses showed 2 different points of view: PC1 and PC2, and PC1 and PC3.
Figure 2(A) Heatmap analysis among the 3 analyzed groups (CTRL, DMSO, DxCS) and (B) between CTRL and DxCS.
Functional annotation by DAVID of the Gene Ontology terms of differential proteins, reporting Biological Processes (BP), Cellular Components (CC), and Molecular Functions (MF). Terms refer to a specific Gene Ontology vocabulary describing Biological Processes, Molecular Functions, and Cellular Components, while % represents the percentage of proteins referring to that particular term with statistical significance (p-value) adjusted by the Benjamini test.
| Biological Processes Terms | % | Benjamini | |
|---|---|---|---|
| cellular response to chemical stimulus | 46.2 | 1.8 × 10−5 | 1.8 × 10−2 |
| cellular response to stress | 38.5 | 3.1 × 10−5 | 1.5 × 10−2 |
| response to inorganic substance | 26.9 | 5.7 × 10−5 | 1.9 × 10−2 |
| response to oxygen-containing compound | 38.5 | 6 × 10−5 | 1.5 × 10−2 |
| response to chemical | 57.7 | 1.2 × 10−4 | 2.4 × 10−2 |
| response to stress | 46.2 | 2.8 × 10−4 | 4.5 × 10−2 |
| response to endogenous stimulus | 34.6 | 3.9 × 10−4 | 5.3 × 10−2 |
| regulation of translation | 19.2 | 4 × 10−4 | 4.7 × 10−2 |
| regulation of apoptotic process | 30.8 | 5.2 × 10−4 | 5.6 × 10−2 |
| regulation of cellular amide metabolic process | 19.2 | 5.2 × 10−4 | 5 × 10−2 |
| regulation of programmed cell death | 30.8 | 5.6 × 10−4 | 4.9 × 10−2 |
| posttranscriptional regulation of gene expression | 19.2 | 7.5 × 10−4 | 6 × 10−2 |
| regulation of cell death | 30.8 | 9.4 × 10−4 | 6.9 × 10−2 |
| organonitrogen compound metabolic process | 34.6 | 9.8 × 10−4 | 6.7 × 10−2 |
|
| |||
| extracellular exosome | 60 | 8.2 × 10−9 | 1.4 × 10−7 |
| extracellular vesicle | 60 | 8.8 × 10−9 | 7.6 × 10−7 |
| extracellular organelle | 60 | 9 × 10−9 | 5.2 × 10−7 |
| membrane-bounded vesicle | 64 | 1.2 × 10−8 | 5 × 10−7 |
| vesicle | 64 | 2.3 × 10−8 | 8 × 10−7 |
| cytoplasmic part | 76 | 2.4 × 10−7 | 6.9 × 10−6 |
| cytosol | 48 | 5.7 × 10−7 | 1.4 × 10−5 |
| extracellular region part | 60 | 6.8 × 10−7 | 1.5 × 10−5 |
| extracellular region | 60 | 2.6 × 10−6 | 4.9 × 10−5 |
| cytoplasm | 80 | 5.3 × 10−6 | 9.1 × 10−5 |
| intracellular part | 80 | 7 × 10−4 | 1.1 × 10−2 |
| intracellular organelle | 76 | 7.4 × 10−4 | 1.1 × 10−2 |
|
| |||
| RNA binding | 36 | 2.8 × 10−4 | 5 × 10−2 |
| purine ribonucleoside triphosphate binding | 36 | 3.9 × 10−4 | 3.5 × 10−2 |
| purine ribonucleoside binding | 36 | 4 × 10−4 | 2.4 × 10−2 |
| ribonucleoside binding | 36 | 4.1 × 10−4 | 1.9 × 10−2 |
| purine nucleoside binding | 36 | 4.1 × 10−4 | 1.9 × 10−2 |
| nucleoside binding | 36 | 4.2 × 10−4 | 1.5 × 10−2 |
| purine ribonucleotide binding | 36 | 4.6 × 10−4 | 1.4 × 10−2 |
| purine nucleotide binding | 36 | 4.8 × 10−4 | 1.3 × 10−2 |
| ribonucleotide binding | 36 | 4.9 × 10−4 | 1.1 × 10−2 |
| ATP binding | 32 | 6 × 10−4 | 1.2 × 10−2 |
| adenyl ribonucleotide binding | 32 | 7.1 × 10−4 | 1.3 × 10−2 |
| adenyl nucleotide binding | 32 | 7.4 × 10−4 | 1.2 × 10−2 |
| small molecule binding | 40 | 8.6 × 10−4 | 1.3 × 10−2 |
Enrichment analysis of the identified proteins by Enrichr software. The table reports chemical substances related to our proteins by DSigDB, with relative p-values and gene names of differential proteins related to the terms.
| Term | Genes | |
|---|---|---|
| (17S)-17-hydroxy-13,17-dimethyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one CTD 00007088 | 1.39 × 10−7 | PDXK; PRDX1; ASNS; TALDO1; HYOU1; EEF2; PAK2; ACTG1 |
| 67526-95-8 CTD 00007263 | 1.83 × 10−10 | TRAP1; TST; MVP; G3BP1; ANXA5; ASNS; HYOU1; PFAS; ACTG1 |
| Vorinostat CTD 00003560 | 1.43 × 10−11 | TRAP1; PRDX1; ANXA5; TALDO1; STRAP; BLVRB |
| troglitazone CTD 00002415 | 1.53 × 10−12 | HSPH1; MVP; PRDX1; ANXA5; ASNS; ACTG1 |
| chlortetracycline HL60 DOWN | 2.94 × 10−12 | PDXK; HSPH1; TST; PRDX1; CRYZL1; UBA1; PAK2 |
| clonidine HL60 DOWN | 3.74 × 10−11 | HSPH1; PFAS; EIF4E |
| lobeline HL60 DOWN | 4.72 × 10−12 | PDXK; HSPH1; G3BP1; CRYZL1; TALDO1; PFAS; PAK2; EIF4E |
| PERHEXILINE CTD 00006493 | 4.79 × 10−11 | ASNS; EIF4E |
| POTASSIUM DICHROMATE CTD 00006598 | 6.61 × 10−11 | TRAP1; MVP; PRDX1; ASNS; UBA1 |
| atrazine CTD 00005450 | 6.7 × 10−11 | TRAP1; GSTM2; HSPH1; TST; MVP; PRDX1; G3BP1; ANXA5; |
| cyproheptadine PC3 UP | 7.38 × 10−11 | ASNS; HYOU1 |
| clindamycin HL60 DOWN | 7.75 × 10−11 | TRAP1; PDXK; PITRM1; PRDX1; CRYZL1; ASNS; TALDO1; PAK2 |
| Copper sulfate CTD 00007279 | 8.72 × 10−10 | TRAP1; PDXK; MVP; ANXA5; ASNS; TALDO1; ACTG1; KLC4; |
| tanespimycin SKMEL5 UP | 9.42 × 10−11 | HSPH1; ASNS |
Enrichment analysis of the identified proteins by Enrichr software reporting molecular pathways by the BioPlanet2019 database, with relative p-values and gene names of differential proteins related to the terms.
| Term | Genes | |
|---|---|---|
| Eukaryotic protein translation | 0.002 | EEF2; EIF4E |
| TGF-beta signaling pathway | 0.002 | TRAP1; STRAP; PAK2 |
| Translation factors | 0.002 | EEF2; EIF4E |
| HIV-1 Nef as negative effector of Fas and TNF | 0.003 | PAK2; ACTG1 |
| Signaling events mediated by hepatocyte growth factor receptor (c-Met) | 0.005 | PAK2; EIF4E |
| Unfolded protein response | 0.005 | ASNS; HYOU1 |
| Sulfide oxidation to sulfate | 0.006 | TST |
| Heme degradation | 0.006 | BLVRB |
| Vitamin B6 metabolism | 0.008 | PDXK |
| eIF4E release | 0.008 | EIF4E |
Figure 3Enrichment analysis by MetaCore of Diseases (by Biomarkers). Orange histograms represent enrichment for human homolog proteins. Blue histograms represent enrichment for differential rat proteins.